These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34001017)

  • 1. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
    Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
    BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
    Idvall I; Andersson C; Fallenius G; Ingvar C; Ringberg A; Strand C; Akerman M; Fernö M
    Acta Oncol; 2001; 40(5):653-9. PubMed ID: 11669340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal carcinoma
    Zhu M; Kuang Y; Jiang Z; Liu J; Zhang H; Zhao H; Luo H; Chen Y; Peng Y
    Gland Surg; 2024 Apr; 13(4):512-527. PubMed ID: 38720675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
    Schorr MC; Pedrini JL; Savaris RF; Zettler CG
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
    Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
    J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
    Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
    Yan M; Bomeisl P; Gilmore H; Harbhajanka A
    Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
    Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
    Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.
    Zhou H; Yu J; Wang X; Shen K; Ye J; Chen X
    Sci Rep; 2022 Feb; 12(1):2169. PubMed ID: 35140303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.
    Wang X; Liu D; Zeng X; Jiang S; Li L; Yu T; Zhang J
    Cancer Imaging; 2021 Jan; 21(1):4. PubMed ID: 33413654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.